Formulated with synergistic botanical compounds that act on multiple stages of the HPV lifecycle—from viral integration and replication to immune modulation—providing a comprehensive local intervention solution.
权诺柠®融合中药复方与现代机制研究,覆盖HPV整合、复制、衣壳装配等多个靶点,通过成分协同作用,有效干预病毒生命周期关键环节。
The product contains no hormones, antibiotics, or alcohol. It is designed to be pH-compatible with the vaginal environment, suitable for long-term use, and ideal for women with sensitive systems.
全配方不含激素、抗生素及酒精,适用于长期使用与敏感体质女性,适配阴道弱酸性环境,增强局部免疫,守护宫颈健康。
In a real-world clinical study with 200 HPV-positive women, Quannuo Ning® achieved an 88% viral clearance rate after 6 months of use (95% CI: 83–92%), significantly outperforming commonly used interferon-based products.
真实世界研究数据显示,连续使用6个月后高危型HPV感染转阴率达88%(95%CI: 83–92%),显著优于同类干扰素类产品。
Featuring a proprietary blend of berberine, baicalin, matrine, ellagic acid, and emodin, the formulation provides antiviral, anti-inflammatory, and mucosal repair benefits backed by pharmacological research.
核心成分包括大黄素、黄芩苷、蛇床子素、苦参碱、鞣花酸等,具备清热解毒、抗病毒、免疫激活与黏膜修复等多重药理机制。
Quannuo Ning® has completed industrial-scale GMP manufacturing validation and received domestic registration approval. A full-spectrum supply chain and delivery system is in place for nationwide deployment.
权诺柠®已完成GMP级生产验证与消字号注册备案,配方定型、柔性供应链与全渠道交付体系已构建完成,即刻具备大规模市场投放能力。
Designed for women who missed the HPV vaccine, already infected, or in clinical “watch-and-wait” stages, Quannuo Ning® fills a critical gap with a science-backed, non-invasive therapeutic option.
为未接种疫苗者、感染后无有效药物者、宫颈病变观察期人群提供“非手术干预窗口”解决方案,填补临床治疗空白。
Copyright © 2025 Flatbird Therapeutics - All Rights Reserved.
ATP Ventures Partner Company
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.